uniQure Investor Relations Material
Latest events
Status Update
uniQure
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from uniQure N.V.
Access all reports
uniQure N.V. is a biotechnology company that develops gene therapies for the treatment of genetic diseases. The company uses viral vector platforms to deliver therapeutic genes to targeted tissues. It focuses on research, clinical development, and manufacturing of gene-based treatments. The company is headquartered in Amsterdam, Netherlands, and its shares are listed on the NASDAQ.
Key slides for uniQure N.V.
Study Update
uniQure N.V.
Study Update
uniQure N.V.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
QURE
Country
🇺🇸 United States